FDA批准非小细胞肺癌的辅助疗法,疾病复发率降低80%

2021-01-11 秘丛丛 亿欧

FDA批准将阿斯利康公司开发的第三代EGFR抑制剂Tagrisso(osimertinib,奥希替尼)作为首个辅助疗法,用作治疗肿瘤具有特定类型基因突变的非小细胞肺癌(NSCLC)患者。

FDA批准将阿斯利康公司开发的第三代EGFR抑制剂Tagrisso(osimertinib,奥希替尼)作为首个辅助疗法,用作治疗肿瘤具有特定类型基因突变的非小细胞肺癌(NSCLC)患者。

FDA肿瘤学高级研究中心主任理查德·帕兹杜尔表示:“今天Tagrisso获批,可以在让更多NSCLC患者可能在疾病更早阶段就接受这款靶向疗法的治疗。”

在一项有682名患者参与的随机双盲与安慰剂的对照试验中,共有339名患者每天口服一次Tagrisso,343名患者在手术和标准辅助化疗恢复后接受安慰剂。根据研究结果,与接受安慰剂的患者相比,服用Tagrisso患者的疾病复发率降低80%。

肺癌是世界上最常见的癌症之一,也是全球癌症相关死亡的主要原因。非小细胞肺癌约占肺癌总数的80%。其中,大约20%的非小细胞肺癌患者会携带表皮生长因子受体(EGFR)突变。

在美国,2020年约22.9万人被诊断出患有肺癌,其中76%的病例是非小细胞肺癌。大约20%的非小细胞肺癌患者将具有表皮生长因子受体(EGFR)突变,这是一种蛋白质上的突变,可引起细胞快速生长有助于癌症扩散。约有30%的非小细胞肺癌患者肿瘤可通过手术切除,这些患者可能是Tagrisso作为肿瘤切除后辅助治疗的候选者。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059955, encodeId=8edf20599550b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu May 27 21:09:48 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839904, encodeId=e2f51839904a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Feb 26 16:09:48 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650603, encodeId=f2bc1650603a1, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Sun May 16 17:09:48 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922437, encodeId=3d19192243eef, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 23 10:09:48 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798890, encodeId=0e3f1e98890d8, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 06 11:09:48 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915430, encodeId=cdc6915430d6, content=好,可以我爷爷已经死了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01645283926, createdName=乡愁, createdTime=Mon Jan 11 00:25:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2059955, encodeId=8edf20599550b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu May 27 21:09:48 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839904, encodeId=e2f51839904a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Feb 26 16:09:48 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650603, encodeId=f2bc1650603a1, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Sun May 16 17:09:48 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922437, encodeId=3d19192243eef, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 23 10:09:48 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798890, encodeId=0e3f1e98890d8, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 06 11:09:48 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915430, encodeId=cdc6915430d6, content=好,可以我爷爷已经死了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01645283926, createdName=乡愁, createdTime=Mon Jan 11 00:25:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
    2021-02-26 bugit
  3. [GetPortalCommentsPageByObjectIdResponse(id=2059955, encodeId=8edf20599550b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu May 27 21:09:48 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839904, encodeId=e2f51839904a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Feb 26 16:09:48 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650603, encodeId=f2bc1650603a1, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Sun May 16 17:09:48 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922437, encodeId=3d19192243eef, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 23 10:09:48 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798890, encodeId=0e3f1e98890d8, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 06 11:09:48 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915430, encodeId=cdc6915430d6, content=好,可以我爷爷已经死了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01645283926, createdName=乡愁, createdTime=Mon Jan 11 00:25:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2059955, encodeId=8edf20599550b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu May 27 21:09:48 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839904, encodeId=e2f51839904a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Feb 26 16:09:48 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650603, encodeId=f2bc1650603a1, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Sun May 16 17:09:48 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922437, encodeId=3d19192243eef, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 23 10:09:48 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798890, encodeId=0e3f1e98890d8, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 06 11:09:48 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915430, encodeId=cdc6915430d6, content=好,可以我爷爷已经死了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01645283926, createdName=乡愁, createdTime=Mon Jan 11 00:25:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2059955, encodeId=8edf20599550b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu May 27 21:09:48 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839904, encodeId=e2f51839904a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Feb 26 16:09:48 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650603, encodeId=f2bc1650603a1, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Sun May 16 17:09:48 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922437, encodeId=3d19192243eef, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 23 10:09:48 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798890, encodeId=0e3f1e98890d8, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 06 11:09:48 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915430, encodeId=cdc6915430d6, content=好,可以我爷爷已经死了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01645283926, createdName=乡愁, createdTime=Mon Jan 11 00:25:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2059955, encodeId=8edf20599550b, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Thu May 27 21:09:48 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839904, encodeId=e2f51839904a4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Feb 26 16:09:48 CST 2021, time=2021-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650603, encodeId=f2bc1650603a1, content=<a href='/topic/show?id=fde093e068f' target=_blank style='color:#2F92EE;'>#辅助疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93706, encryptionId=fde093e068f, topicName=辅助疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfce24047456, createdName=sodoo, createdTime=Sun May 16 17:09:48 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922437, encodeId=3d19192243eef, content=<a href='/topic/show?id=4a80425e534' target=_blank style='color:#2F92EE;'>#复发率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42575, encryptionId=4a80425e534, topicName=复发率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 23 10:09:48 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798890, encodeId=0e3f1e98890d8, content=<a href='/topic/show?id=b677e06626a' target=_blank style='color:#2F92EE;'>#疾病复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70662, encryptionId=b677e06626a, topicName=疾病复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Sep 06 11:09:48 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915430, encodeId=cdc6915430d6, content=好,可以我爷爷已经死了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01645283926, createdName=乡愁, createdTime=Mon Jan 11 00:25:00 CST 2021, time=2021-01-11, status=1, ipAttribution=)]
    2021-01-11 乡愁

    好,可以我爷爷已经死了

    0

相关资讯

Eur Radiol:非小细胞肺癌患者前纵隔淋巴结到底有没有转移?

非小细胞肺癌患者前纵隔淋巴结到底有没有转移?

FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格”

肿瘤学公司Merus今天宣布,美国食品药品监督管理局(FDA)已授予Zenocutuzumab(Zeno)治疗具有NRG1基因融合的转移性实体瘤患者的“快速通道资格”。

Nat Commun:武汉大学等多单位合作!钟波/林丹丹/褚倩揭示非小细胞肺癌新的潜在的治疗靶标

肺癌是最普遍的癌症,也是与癌症相关的死亡的主要原因,每年在全球造成200万以上的新诊断和170万死亡。大约85%的被诊断肺癌是非小细胞肺癌(NSCLC),其中50%以上的腺癌和30%的鳞状癌。免疫检查

Nature Cancer:非小细胞肺癌免疫疗法效果预测标志物-HLA-B44超型

人类白细胞抗原(HLA)-B被认为是疾病预后差异的主要决定因素,最近有证据表明其在免疫检查点阻断疗法(ICB)的疗效中起作用。研究发现HLA-B44超型可用于NSCLC免疫治疗疗效预测。

LORBRENA(lorlatinib)治疗先前未经治疗的ALK阳性肺癌的sNDA已被美国FDA接受优先审查

辉瑞公司今天宣布,美国食品和药品监督管理局(FDA)已接受对LORBRENA®(lorlatinib)的补充新药申请(sNDA),以作为ALK阳性转移性非小细胞肺癌(NSCLC)的一线治疗药物